Strong revenue growth (374% YoY), significant improvement in net losses (50% reduction), major regulatory milestones (FDA clearance and CE certification), and solid cash position ($21.7M liquid assets) support positive outlook. However, core operational revenue remains modest at ~$2.9M excluding the one-time settlement, and the company is still unprofitable, which tempers the sentiment from highly positive to moderately positive.
Articles that tag PLSM but are mainly about other companies.
Selected for Israel's Healthcare AI Regulatory Sandbox Program with $1 million government backing; provides collaboration opportunities with regulators and healthcare institutions to develop AI tools for ultrasound platform.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
